ThermoGenesis Holdings (STU:THR) 5-Year EBITDA Growth Rate : 64.40% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is ThermoGenesis Holdings 5-Year EBITDA Growth Rate?

ThermoGenesis Holdings's EBITDA per Share for the three months ended in Mar. 2024 was €-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 61.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 64.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 51.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ThermoGenesis Holdings was 73.30% per year. The lowest was -193.20% per year. And the median was 15.20% per year.

Competitive Comparison of ThermoGenesis Holdings's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, ThermoGenesis Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ThermoGenesis Holdings's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's 5-Year EBITDA Growth Rate falls into.

ThermoGenesis Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

ThermoGenesis Holdings (STU:THR) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

ThermoGenesis Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

ThermoGenesis Holdings (STU:THR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

THMO:USA

Address

2711 Citrus Road, Rancho Cordova, CA, USA, 95742

Website

https://www.thermogenesis.com

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.